A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines

Rheumatology

Volumn 44, Issue 7, 2005, Pages 921-924

  Price Forbes, A N ^a   Callaghan, R ^b   Allen, M E ^a   Rowe, Ian F ^c  

^a UNIVERSITY HOSPITALS COVENTRY AND WARWICKSHIRE NHS TRUST   (United Kingdom)

^b UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

^c WORCESTERSHIRE ROYAL HOSPITAL   (United Kingdom)

Author keywords

COX 2 inhibitors; NICE guidelines; NSAIDs; Osteoarthritis; Rheumatoid arthritis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CELECOXIB; CORTICOSTEROID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; ETODOLAC; GASTROINTESTINAL AGENT; MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; ROFECOXIB; WARFARIN; MEMBRANE PROTEIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; PTGS2 PROTEIN, HUMAN;

AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONTROLLED STUDY; DATA ANALYSIS; DEMOGRAPHY; DRUG INDICATION; DRUG SELECTIVITY; DRUG USE; FREQUENCY ANALYSIS; GASTROINTESTINAL SYMPTOM; HEALTH CARE ORGANIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL AUDIT; OSTEOARTHRITIS; OUTPATIENT DEPARTMENT; PRACTICE GUIDELINE; PRESCRIPTION; PRIORITY JOURNAL; QUESTIONNAIRE; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK ASSESSMENT; RISK FACTOR; UNITED KINGDOM; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; DRUG ADMINISTRATION; GASTROINTESTINAL DISEASE; MULTICENTER STUDY; STATISTICS;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS, RHEUMATOID; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG UTILIZATION REVIEW; ENGLAND; GASTROINTESTINAL DISEASES; GUIDELINE ADHERENCE; HUMANS; MEDICAL AUDIT; MEMBRANE PROTEINS; OSTEOARTHRITIS; OUTPATIENT CLINICS, HOSPITAL; PRACTICE GUIDELINES; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RISK FACTORS;

EID: 22844441540     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keh642     Document Type: Article

References (29)

1. Department of Health. Prescription cost analysis: England 2003. www.publications.doh.gov.uk/stats/pca2003.htm
2. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 1999;340:1888-99.
3. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1991;112:1000-16.
4. Seager JM, Hawkey CJ. ABC of the upper gastrointestinal tract: indigestion and nonsteroidal anti-inflammatory drugs. BMJ 2001:323:1236-39.
5. Whelton A. Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999:106:13S-24S.
6. Todesco S. Special considerations in the use of NSAIDs in the elderly. Eur J Rheumatol Inflamm 1994;14:7-13.
7. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to the use of nonsteroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991;115:787-196.
8. Fick DM, Cooper JW, Wade JL, Waller JL, Maclean JR, Beers MH. Updating the Beers criteria for potentially inappropriate medication use in older adults: Results of a US consensus panel of experts. Arch Intern Med 2004;163:2716-24.
9. MacLean CH. Quality indicators for the management of osteoarthritis in vulnerable elders. Ann Intern Med 2001:135:711-21.
10. Hawkey CJ. The gastroenterologist's caseload: Contribution of the rheumatologist. Semin Arthritis Rheum 1997:26(6 Suppl. 1):11-5.
11. Tramer MR, Moore RA, Reynolds JM, McQuay HI. Quantitative estimation of rare events which follow a biological progression: A new model applied to chronic NSAID use. Pain 2000;85:169-82.
12. Moore C, Phillips C. Cost of NSAID adverse effects to the UK National Health Service. J Med Economics 1999;2:45-55.
13. Blower AL, Brooks A, Fenn CG et al. Emergency admissions for upper gastrointestinal disease and their relation to NSAID use. Aliment Pharmacol Ther 1997;11:283-91.
14. Hawkey CJ, Cullen DJ, Greenwood DC et al. Prescribing of nonsteroidal anti-inflammatory drugs in general practice: Determinants and conscquences. Aliment Pharmacol Ther 1997;11:293-8.
15. Brooks P, Emery P, Evans JF et al. Interpreting the clinical significance of the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2. Rheumatology 1999:38:779-88.
16. Simon LS, Weaver AL, Graham DY et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: A randomized controlled trial. JAMA 1999;282:1921-8.
17. National Institute for Clinical Excellence. Technology Appraisal 27 (July 2001). Guidance on the use of cyclo-oxygenase (Cox) II selective inhibitors, celecoxib, rofecoxib, meloxicam and etodolac for osteoarthritis and rheumatoid arthritis. London: NICE, 2001.
18. Ledingham JM, Wood A, McCrae FC et al. Non-steroidal anti-inflammatory drug (NSAID), Cox-2 inhibitor (Cox-2) and gastro-protective agent (GPA) use in a rheumatology out-patient (OP) population. Rheumatology 2003;42(Suppl. 1):268.
19. Lee JB, LaPortes SJ, Chan AT, McNally J. Audit of the use of cyclooxygenase (COX)II selective inhibitors according to the NICE guidelines. Rheumatology 2001:41(Suppl. 1):56.
20. Smalley W, Stein CM, Arbogast PG, Eisen G, Ray WA, Griffin M. Underutilisation of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs. Arthritis Rheum 2002;46: 2195-200.
21. Sturkenboom MC, Burke TA, Dieleman JP, Tangelder MJ, Lee F, Goldstein JL. Underutilisation of preventive strategies in patients receiving NSAIDs. Rheumatology 2003; 42(Suppl. 3):iIi23-31.
22. Koch M, Dezi A, Ferrario F, Capurso L. Prevention of nonsteroidal anti-inflammatory drug-induced gastrointestinal mucosal injury. Arch Intern Med 1996:156:2321-32.
23. Hansen JM, Hallas J, Lauritson JM, Bytzer P. Non-steroidal anti-inflammatory drugs and complications: A risk factor analysis for clinical decision-making. Scand J Gastroenterol 1996;31:126-30.
24. Laine L, Bombardier C, Hawkey CJ et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 2002:123:1006-12.
25. Ritz E. Renal dysfunction: A novel indicator and potential promoter of cardiovascular risk. Clin Med 2003;3:357-60.
26. Culleton BF, Larson MG, Wilson PW et al. Cardiovascular disease and mortality in a community-based cohort with mild renal insufficiency. Kidney Int 1999;56:2214-9.
27. Merck announces voluntary worldwide withdrawal of VIOXX®. Whitehouse Station, NJ, 2004. Merck & Co. www.vioxx.com.
28. Medicines and Healthcare Products Regulatory Agency. Advice on the use of celecoxib and other selective cox-2 inhibitors in light of concerns about cardiovascular safety. London: MHRA, 2004. www.mhra.gov.uk
29. Dieppe PA, Ebrahim S, Martin RM, Jüni P. Lessons from the withdrawal of rofecoxib. BMJ 2004:329:867-8.